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ABSTRACT
Background. The endocrinology of skeletal muscle is highly complex and many issues
about hormone action in skeletal muscle are still unresolved. Aim of the work is to
improve our knowledge on the relationship between skeletal muscle and 17β-estradiol.
Methods. The skeletal muscle cell line C2C12 was treated with 17β-estradiol, the
oxytocin peptide and a combination of the two hormones. The mRNA levels of
myogenic regulatory factors, myosin heavy chain, oxytocin, oxytocin receptor and
adipogenic factors were analysed in C2C12 myotubes.
Results. It was demonstrated that C2C12myoblasts andmyotubes express oxytocin and
its receptor, in particular the receptor levels physiologically increase in differentiated
myotubes. Myotubes treated with 17β-estradiol overexpressed oxytocin and oxytocin
receptor genes by approximately 3- and 29-fold, respectively. A decrease in the
expression of fatty acid binding protein 4 (0.62-fold), a fat metabolism-associated
gene, was observed in oxytocin-treated myotubes. On the contrary, fatty acid binding
protein 4 was upregulated (2.66-fold) after the administration of the combination of
17β-estradiol and oxytocin. 17β-estradiol regulates oxytocin and its receptor in skeletal
muscle cells and they act in a synergic way on fatty acid metabolism.
Discussion. Oxytocin and its receptor are physiologically regulated along differen-
tiation. 17β-estradiol regulates oxytocin and its receptor in skeletal muscle cells.
17β-estradiol and oxytocin act in a synergic way on fatty acid metabolism. A better
understanding of the regulation of skeletal muscle homeostasis by estrogens and
oxytocin peptide could contribute to increase our knowledge of muscle and its
metabolism.
Subjects Cell Biology, Molecular Biology, Veterinary Medicine
Keywords Estrogen, Oxytocin, Skeletal muscle cell, Gene expression regulation
INTRODUCTION
Hormones such as estrogens, testosterone, growth hormone, insulin, insulin-like growth
factor-I and glucocorticoids have a profound influence on skeletal muscle and they are
important regulators of the remodelling process. Anabolic hormones stimulate muscle
growth in animals and humans by increasing protein synthesis, by decreasing protein
breakdown or both. While the anabolic effects of androgens are well known (Dubois et
al., 2012), the effects of estrogens on skeletal muscle anabolism have only been discovered
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recently (Greising et al., 2009), in particular estrogens have been shown to stimulate muscle
repair and regenerative processes (Enns & Tiidus, 2010).
Skeletal muscle myogenesis is controlled by myogenic regulatory factors (MRFs), such
as myogenic differentiation 1 (MYOD), myogenic factor 5 (MYF5), myogenin (MYOG)
and myogenic factor 6 (MYF6), and mature skeletal muscle expresses structural muscle
proteins, such as myosin heavy chain (MYH) and tropomyosin (Charbonnier et al., 2002).
MRFs are expressed in a time-dependent manner and regulate differentiation of muscular
cells, in particular they control the fusion of myoblasts (MBs) (mononucleated muscle
precursor) into multinucleated cells called myotubes (MTs) (Dedieu et al., 2002).
Growth-promoting agents are purported to increase skeletal muscle fiber size and they
could be illegally used to improve sport performances or meat production. Previous studies
described the effect of 17β-estradiol (E2) on the gene expression levels in skeletal muscle
of veal calves. In particular, De Jager et al. (2011) and Divari et al. (2013) demonstrated a
strong increase in the expression of the oxytocin (Oxt ) precursor and oxytocin receptor
(Oxtr) genes in the skeletal muscle of E2-treated veal calves and an intense raise of the
plasmatic concentration of circulating oxytocin peptide (OXT). The high serum OXT
concentration was likely due to the estrogen influence on OXT production within the
supraoptic and paraventricular nuclei of the hypothalamus and/or its release from the
posterior pituitary into the blood stream (Chung, McCabe & Pfaff, 1991; Nomura et al.,
2002). Moreover, Oxt precursor gene is increased in bovine skeletal muscle in the late
stages of foetal development (De Jager et al., 2011), suggesting that OXT could have a role
in muscle growth during both foetal and postnatal development in animals (De Jager et al.,
2011; Divari et al., 2013) and that E2 can have a regulatory effect on OXT production in
skeletal muscle.
In mammals OXT is mainly synthesized in the central nervous system and it induces
uterine contractions during parturition and milk ejection during lactation. In recent years,
the classic concept of OXT action has been greatly expanded because of the discovery of
novel sites ofOXTandOXT receptor (OXTR) gene andprotein expression such as the testes,
ovaries, heart and lungs (Assinder et al., 2000; Jankowski et al., 2004;Kiss & Mikkelsen, 2005;
Péqueux et al., 2005; Zingg & Laporte, 2003). Moreover, E2 was demonstrated to induce
OXT/OXTR overexpression in several of those (Feng et al., 2009; Sharma, Handa & Uht,
2012). Many studies demonstrated that OXT has various metabolic effects in particular
on muscular metabolism and regeneration, glucose metabolism, lipid profile and insulin
sensitivity. In skeletalmuscleOXT exerts its activity promoting glucose uptake and inducing
lypolisis (Elabd et al., 2014; Elabd & Sabry, 2015). Similarly, E2 is intensively studied for its
influence on energy balance, skeletal muscle and adipose tissue metabolism and glucose
uptake regulation, but its role is still partially unclear (Ropero et al., 2008). In this regard, an
important role on cell metabolism is played by fatty acid binding proteins 3 and 4 (FABP3
and 4) and peroxisome proliferator-activated receptor gamma (PPARG) which mediate
fatty acid translocations, regulate cholesterol metabolism, participate to several signalling
cascades (Makowski & Hotamisligil, 2004) and control adipogenesis (Jeong & Yoon, 2011).
Aim of the work was to evaluate the physiological expression of OXT and OXTR in MBs
and MTs and to asses a relationship between estrogen administration and OXT/OXTR
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expression in a reproducible model of skeletal muscle. In particular, it was verified if E2
and OXT could influence myofibers metabolism gene regulation. For this purpose, the
C2C12 cell line was treated with E2, OXT or a combination of both molecules to assess the
regulation of myogenic regulatory factors genes (MRFs), myosin heavy chain (Myh) and
some factors involved in adipogenesis, such Fabp3, Fabp4 and Pparg.
MATERIALS AND METHODS
C2C12 cell culture
C2C12 murine myoblasts (MBs) (European Collection of Cell Cultures, ECACC No.
91031101, Salisbury, UK) were grown in Dulbecco’s modified Eagle’s medium (DMEM;
Sigma, St. Louis, MO, USA) supplemented with 10% heat-inactivated foetal bovine serum,
2 mM glutamine (Sigma) and 1% antibiotic antimycotic solution (Sigma). The cultured
cells were maintained in 5% CO2 atmosphere at 37 ◦C. To obtain differentiated myotubes
(MTs), cells at 80% confluencewere switched into differentiationmedium (DM) containing
10% heat-inactivated horse serum.
Phenol red-free medium was used throughout the experiments to avoid its weak
estrogen-like activity.
BT474 cell culture
BT474 (American Type Culture Collection, ATCC R©, HTB-20,Manassas, VA, USA) human
mammary gland carcinoma cells were grown in DMEM supplemented with 10% heat-
inactivated foetal bovine serum, 2 mM glutamine (Sigma) and 1% antibiotic antimycotic
solution (Sigma) as positive control for the enzyme immunoassay (EIA). BT474 cells were
grown in 100 mm petri dishes until 80% confluence, were starved and treated with E2 (10
nM) for 48 h to induce OXT secretion as described by Cassoni et al. (2006).
Experimental design
In all experiments, the sera were stripped with charcoal and dextran as described in Sharma,
Handa & Uht (2012) to remove hormones.
To assess the physiological OXT and OXTR expression level, C2C12 MBs and MTs
were respectively collected at day 3 and day 7. Subsequently, trials of acute and chronic
administration of E2 were conducted on MTs to study gene expression modifications.
For the acute treatment trial, MTs were grown to day 6 and then starved with media
containing stripped horse serum for 24 h before the E2 treatment (Sigma). The MTs were
incubated with E2 (10 nM) at day 7 and then harvested at 0.5, 1, 2, 3, and 4 h of incubation
(adapted from Sharma, Handa & Uht (2012)) to determine the Oxt and Oxtr expression
levels. The control cultures were administered vehicle (Fig. 1).
For the chronic treatment trials, cells were treated with E2 (10 nM) or OXT peptide
(10 µM) (Sigma), or a combination of E2 with OXT peptide (E2-OXT) (10 nM and
10 µM, respectively) every 48 h during differentiation from MB to MT (Fig. 1). OXT
peptide was dissolved in 10 nM citrate buffer to increase its stability at high temperature
(Avanti et al., 2011). Day 7 was chosen to harvest the differentiated MTs and to conduct
the transcriptomic analysis because spontaneous contraction of MTs was observed, which
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Figure 1 Experimental scheme. The C2C12 MBs were maintained in growth medium for 3 days (80–
90% confluence). Myogenic differentiation was then induced from day 3 to day 7 by switching the cells
to differentiation medium (DM). For the experiments involving acute treatment at day 7, the MTs were
incubated with E2 (10 nM) for 0.5, 1, 2, 3, and 4 h. For the experiments involving chronic treatment, the
cells were treated with E2 (10 nM), OXT (10 µM), or combination of E2 and OXT (10 nM and 10 µM,
respectively) every 48 h during differentiation from MBs to MTs. The cells were harvested for qPCR anal-
ysis and western blotting.
is commonly associated with the maturation of MTs in culture. The levels of the Oxt, Oxtr,
Myf6, Myf5, Myod, Myog Myh, Fabp3, Fabp4 and Pparg mRNAs were determined. Each
experiment was performed five times in duplicate.
Myotube fusion index
The fusion index is a frequently used index of muscle cell differentiation and provides
a measure of the proportion of the total cell populace that has fused (Agley et al., 2012).
The fusion rate of the MTs that were chronically treated with E2, OXT and E2-OXT was
evaluated at day 7 and compared to the untreated cell culture. The cells were washed with
PBS and fixed in 10% neutral buffered formalin for 10 min. The fixed MTs were rinsed
twice with PBS and stained with haematoxilin and eosin (H&E). Five control and five
treated wells from independent experiments were analysed. For each well, the nuclei within
the MTs and the nuclei of the unfused cells were counted in 10 randomly selected fields
(200×) with Image Pro R© plus (Version 3.0.1) software. A cell containing three or more
nuclei was considered to be a MT (Ge, Yu & Jiang, 2012). For each slide, the fusion index
percentage was calculated as (the number of fused nuclei/total nuclei)*100.
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Table 1 Primer sequences for qPCR.
Gene (RefSeq ID) Forward primer (5′–3′) Reverse primer (5′–3′) Amplicon size (bp)
Oxt (NM_011025) TGGCTTACTGGCTCTGACCT GAGACACTTGCGCATATCCA 94
Oxtr (NM_001081147) GCACGGGTCAGTAGTGTCAA CCACATCTGCACGAAGAAGA 120
Myod (NM_010866) TACAGTGGCGACTCAGATGC TAGTAGGCGGTGTCGTAGCC 116
Myf5 (NM_008656) CTGTCTGGTCCCGAAAGAAC AAGCAATCCAAGCTGGACAC 103
Myog ( NM_031189) CGATCTCCGCTACAGAGGC GTTGGGACCGAACTCCAGT 115
Myf6 (NM_008657) GGCTGGATCAGCAAGAGAAG AGGAAATCCGCACCCTCA 91
Myh (NM_030679) CGCAAGAATGTTCTCAGGCT GCCAGGTTGACATTGGATTG 110
Fabp3 (NM_010174) TAGGGAGCTAGTTGACGGGAA ACGCCTCCTTCTCATAAGTCC 83
Fabp4 ( NM_024406) GCAGAAGTGGGATGGAAAGT CTTGTGGAAGTCACGCCTTT 96
Pparg (NM_001127330) CGAGTCTGTGGGGATAAAGC TTCAATCGGATGGTTCTTCG 92
Ppia (NM_008907) GCAAATGCTGGACCAAACAC TCACCTTCCCAAAGACCACAT 97
Notes.
Oxt , oxytocin gene; Oxtr , oxytocin receptor gene;Myod , myogenic differentiation 1 gene;Myf5, myogenic factor 5 gene;Myog , myogenin gene;Myf6 , myogenic factor 6 gene;
Myh, myosin heavy chain gene; Fabp3, fatty acid binding protein 3 gene; Fabp4, fatty acid binding protein 4 gene; Pparg , peroxisome proliferator-activated receptor gamma
gene; Ppia, peptidylprolyl isomerase A.
RNA extraction and relative quantification by qPCR
The total RNA fromeach cell culture samplewas extracted usingTRIzol reagent (Invitrogen,
Life Technologies, Carlsbad, CA,USA), according to themanufacturer’s protocol. The RNA
concentration was determined by UV-Visible spectrophotometry and the RNA integrity
was verified by automated gel electrophoresis system (Experion Instrument; Bio-Rad,
Hercules, CA, USA). The cDNAs were synthesized from 1 µg of the total RNA using
the QuantiTect Reverse Transcription Kit (Qiagen, Hilden, D), which included DNase
reaction, according to the manufacturer’s protocol.
To determine the relative amounts of specific Oxt, Oxtr, MRFs, Myh, Fabp3, Fabp4,
and Pparg transcripts, the cDNAs were subjected to qPCR using the IQ5 detection system
(Bio-Rad) and the IQ SYBR Green Supermix (Bio-Rad). The peptidylprolyl isomerase A
(Ppia) cDNA was used as housekeeping gene control. The primer sequences were designed
using Primer 3 (vers. 0.4.0) (Untergrasser et al., 2012) or Primer-BLAST (Ye et al., 2012),
except for those for the Myh (Feng et al., 2009) and Ppia (Nishimura et al., 2008) genes,
which were based on the literature (Table 1).
The levels of gene expression were calculated using the relative quantification assay
based on the comparative Cq method (11Cq method) (Bustin et al., 2009). The relative
abundances of each transcript were recorded as 2−11Cq (fold increase) (Pfaffl, 2004).
Regarding the comparison of physiological Oxt and Oxtr expression in untreated MBs
and MTs, the gene expression levels were described as mRNA arbitrary units (2−1Cq).
Western blot analysis
The total proteins were extracted from cell lysate using RIPA buffer (50 mM Tris, pH
8.0, 150 mM NaCl, 1.0% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS and
2 mM EDTA) supplemented with a protease inhibitor cocktail (Sigma). The protein
concentration was determined using the Bio-Rad DC Protein Assay. Proteins were boiled
at 95 ◦C for 5 min in Leammli buffer and 35 µg of the total protein were resolved by
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10% SDS–PAGE for OXTR assessment. The proteins were blotted to Hybond-P PVDF
membrane (Amersham Biosciences, Piscataway, NJ, USA) using the Mini Trans-Blot
cell (Bio-Rad). The blotted membranes were blocked with bløk-CH Buffer (Millipore
KGaA, Darmstadt, D) for 1 h at room temperature, followed by overnight 4 ◦C incubation
with the primary goat polyclonal anti-OXTR antibody (1:200; Santa Cruz Biotechnology).
Proteins of rat heart was used as positive control (C+) for OXTR as other authors described
(Jankowski et al., 1998). The membranes were subsequently incubated with a secondary
horseradish peroxidase (HRP)-conjugated anti-goat antibody (1:10000), developed using
the SuperSignal West Pico IgG Detection Kit (Thermo Fisher Scientific, Waltham, MA,
USA) and signal was recorded on CL-XPosure X-ray film (Thermo Fisher Scientific) or by
Chemi-Doc MP System (Bio-Rad). α-tubulin (1:10000, clone B-5-1-2; Sigma) was used as
total protein loading control. Densitometric analysis of the bands was performed by the
public domain ImageJ software (US National Institutes of Health, Bethesda, MD, USA;
http://rsb.info.nih.gov/nih-image/), (n= 3).
Enzyme immunoassay (EIA)
To study OXT peptide expression, the culture media fromMBs and MTs, from the acutely
treated MTs and BT474 were collected and immediately stored at −80 ◦C until further
analysis. The soluble OXT peptide concentration was measured by enzyme immunoassay
methodology using the EIA kit developed by Cayman Chemical (Tallinn, EE). The
manufacturer reports a limit of detection (LOD) for this kit of approximately 18 pg/
ml. OXT was extracted from 10 ml of culture medium aliquots using a solid-phase
extraction (SPE), 1,000 mg C-18 Sep- Pack column (Supelco; Sigma-Aldrich, St. Louis,
MO, USA) as previously described (Divari et al., 2013). Then, concentrated samples were
collected in a glass tube and evaporated to dryness under a stream of nitrogen gas; they were
reconstituted in 0.5 ml of assay buffer and immediately measured (concentrated 20-fold).
The absorbance at 405 nm was read using Microplate Reader 680 Model (Bio-Rad) and a
standard curve was created using a four parameter logistic function.
Statistical analysis
All cell culture experiments were conducted in duplicate and were repeated five separate
times.
All statistical analyses were performed using the GraphPad Prism 4 (vers. 4.03) software
(GraphPad Inc., San Diego, CA, USA). Normal distribution was tested by the Kolmorov-
Smirnov test. Grubbs’ test was used to determine and exclude potential outliers. In the
qPCR experiments in which results were expressed as 2−1Cq, a paired t -test or Wilcoxon
test were applied. For qPCR results expressed as differences in the relative expression
(2−11Cq) of each target gene between the hormone-treated and untreated cells, data were
analysed by ANOVA or Kruskal–Wallis for the acute trial, followed by Dunnett’s or Dunn’s
post test, and by the paired t -test or Mann–Whitney test for chronic trial results. Data are
presented as the means ± SEM from 5 experiments. p< 0.05 was considered significant.
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Figure 2 Oxt and Oxtr mRNA and protein levels in the control MB andMT cultures. (A) The gene ex-
pression results are presented as the means± SEM of Oxt/Ppia and Oxtr/PpiamRNA level and expressed
as 2−1Cq. (B) Western blot of the OXTR protein in the control MB and MT lysates, (C) EIA test for OXT
peptide concentration in culture growth medium expressed as pg/ml, (D) Densitometric analysis of west-
ern blot bands of OXTR. Band intensity was normalized versus the loading control and presented as arbi-
trary units.
RESULTS
Basal levels of OXT and OXTR expression during differentiation of
C2C12 MBs into MTs
The basal levels of Oxt mRNA expression were extremely low in MBs (3.47E−06 mRNA
arbitrary units); while, during myogenic differentiation into MTs, the Oxt mRNA
concentration increased (5.01E−06 mRNA arbitrary units, p< 0.05). Similarly, Oxtr
mRNA expression in MBs was scarse (8.40E−07 mRNA arbitrary units) and increased
in differentiated MTs (4.28E−06 mRNA arbitrary units, p< 0.001) (Fig. 2A). Protein
expression of OXT in MBs and MTs was demonstrated by EIA test (1.50 pg/ml in MBs and
4.26 pg/ml in MTs respectively) (Fig. 2C). OXTR protein was demonstrated and quantified
by western blot (Figs. 2B and 2D).
Effect of acute E2 administration on OXT and OXTR expression in
C2C12 MTs
In the acute assay, Oxt mRNA was upregulated by approximately 3-fold after 0.5 h of E2
incubation (p< 0.01) compared with the control cells. After 3 and 4 h of E2 treatment, the
mRNA levels progressively decreased until control levels (Fig. 3A). Oxtr mRNA levels were
not significantly regulated by treatment (Fig. 3B).
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Figure 3 Effect of the acute E2 treatment on OXT and OXTR expression in theMTs. (A) and (B) Oxt
and Oxtr gene expression in the MTs respectivley. The results are presented as the means± SEM of the
Oxt fold increase expressed as 2−11Cq. The samples were analysed in duplicate in five independent exper-
iments (∗p< 0.05), (C) OXT peptide concentration (pg/ml) in the culture media (10 ml) of the acute E2-
treated MTs. Lysate from E2-treated BT474 cells (BT474+ E2) was used a positive control. The OXT pep-
tide concentrations were determined by EIA Kit. (D) A representative western blot showing the expression
of OXTR in the lysates of the acute E2-treated MTs. α-tubulin was used as loading control. Positive con-
trol (C+) (E) densitometric analysis of western blot bands of OXTR. Band intensity was normalized versus
the loading control and presented as arbitrary units.
The EIA test on the growth media from the examined cell culture showed different OXT
peptide concentration between samples: 7.61 pg/ml of OXT peptide were detected after
0.5 h of E2 administration against the 4.26 pg/ml of OXT of the control sample. The media
from BT474 E2-treated cells was used as positive control for OXT secretion demonstrating
a total OXT concentration of 6.90 pg/ml (Fig. 3C). OXTR protein expression was studied
byWestern blot (Figs. 3D and 3E) and no statistically significant differences were recorded.
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Figure 4 The fusion index. (A) and (B) Representatives images of control culture and E2-treated MTs
respectively (H&E, 50 µm bar), (C) The fusion index percentage of chronic E2-, OXT-, and E2–OXT-
treated MTs was calculated as (the number of fused nuclei/total nuclei)*100.
Effect of chronic hormone administration on MTs fusion index
To study the effect of chronic E2, E2-OXT and OXT treatments on myogenic development
fusion index was studied in MTs and representative images are shown in Figs. 4A and 4B.
The fusion index was not affected by chronic administration of E2 nor by OXT or the
combination of both molecules (Fig. 4C).
Effect of chronic hormone administration on Oxt, Oxtr, MRFs, Myh,
Fabp3, Fabp4 and Pparg gene expression in C2C12 MTs
The MRF mRNA levels in the C2C12 MTs were not significantly regulated by any of the
chronic treatments (Figs. 5A–5C). A mild downregulation of theMyh gene was observed in
the chronically treated cells; in particular E2 induced a significant decrease of approximately
0.90-fold compared with the control culture (p< 0.05) (Fig. 5A). Chronic treatments with
E2-OXT and OXT did not significantly influence the expression of the studied genes
involved in growth and differentiation of the MTs.
Chronic administration of E2 and E2-OXT induced a significant overexpression of the
Oxtr gene. In particular, in the E2-treated cells the levels of theOxtr mRNA were increased
by approximately 29-fold compared with the control culture (p< 0.05) (Fig. 5D) and the
combination of the two hormones induced this mRNA by approximately 11-fold compared
with the control culture (p< 0.05) (Fig. 5F).
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Figure 5 Effect of chronic hormone administration onOxt, Oxtr, MRFs, Myh, Fabp3, Fabp4 and
Pparg gene expression in C2C12MTs. Gene expression of the several genes of interest was studied by
qPCR. (A) Gene expression ofMRFs genes andMyh in MTs treated with E2, (B) Gene expression ofMRFs
genes andMyh in MTs treated with OXT, (C) Gene expression ofMRFs genes andMyh in MTs treated
with E2-OXT, (D) Gene expression of Oxt and Oxtr genes in MTs treated with E2, (E) Gene expression of
Oxt and Oxtr genes in MTs treated with OXT, (F) Gene expression of Oxt and Oxtr genes in MTs treated
with E2-OXT, (G) Gene expression of Fabp3, Fabp4 and Pparg genes in MTs treated with E2, (H) Gene
expression of Fabp3, Fabp4 and Pparg genes in MTs treated with OXT, (I) Gene expression of Fabp3,
Fabp4 and Pparg genes in MTs treated with E2-OXT. The results are presented as the means± SEM of
the Oxt fold increase expressed as 2−11Cq. The samples were analysed in duplicate in five independent
experiments (∗p < 0.05).Myf6, myogenic factor 6 gene;Myog, myogenin gene;Myf5, myogenic factor 5
gene;Myod, myogenic differentiation 1 gene;Myh, myosin heavy chain gene; Oxt, oxytocin gene; Oxtr,
oxytocin receptor gene; Fabp3, fatty acid binding protein 3 gene; Fabp4, fatty acid binding protein 4 gene;
Pparg, peroxisome proliferator-activated receptor gamma gene.
Moreover, chronic administration of E2-OXT in MTs induced a significant
overexpression of Fabp4 (2.66-fold) (Fig. 5I), which is involved in fatty acid handling,
while a decrease in the expression of Fabp4 (0.62-fold) was observed in the OXT-treated
MTs (Fig. 5H)
DISCUSSION
In the present study the expressions of OXT and OXTR genes and proteins were studied in
C2C12 cell line and the modification induced by E2 and/or OXT treatment were analyzed.
We demonstrated for the first time that both C2C12 MBs and MTs express OXT and
OXTR, in particular MBs shown a mild expression level which increased in differentiated
MTs. OXTR is physiological expressed in human MBs (Breton et al., 2002) and in bovine
muscle both Oxt and Oxtr genes are expressed during muscle development (De Jager et
al., 2011). Since we demonstrated that the OXTR expression increases along with MTs
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differentiation, it is likely that the OXT and OXTR system is involved in skeletal muscle
development (Lee et al., 2008).
Successively, the action of E2 on gene expression in C2C12 MTs was studied and we
shown that acute and chronic treatments induced different alterations.
Acute E2 treatments were performed adapting the protocol and time points used by
Sharma, Handa & Uht (2012). In their work a hypothalamic neuronal cell line derived
from embryonic mice treated with E2 shown an overexpression of Oxt mRNA level during
the first hour of treatment and returned to baseline by 2 h. Similarly in C2C12 MTs,
acute treatments with E2 determined the overexpression of Oxt mRNA suggesting that the
expression of the Oxt gene is rapidly upregulated in MTs following E2 administration. We
demonstrated that OXT is expressed in C2C12 MTs and that acute E2 administration can
control its release outside of the cell. Indeed, a higher concentration of OXT in the growth
medium from treated samples was demonstrated compared with control samples by EIA
test. These data suggest that E2 may regulate OXT release from skeletal muscle cells. We
hypothesize that skeletal muscle is able to secrete OXT under E2 stimuli as similarly occurs
in osteoblasts. Indeed, E2 induces abundant OXT production in bone marrow osteoblasts,
with the potential for exerting an anabolic effect on the skeleton (Colaianni et al., 2012)
through an autocrine feed-forward OXT/OXTR loop in which estrogen induces OXT
release from osteoblasts and then OXT acts upon osteoblastic OXTR to further amplify
estrogen action.
The detection of a modest secretory activity in the treated MTs suggests that acute
stimuli with E2 regulate OXT expression and release, activating an OXT/OXTR loop in the
skeletal muscle cells, similarly to the osteoblasts. Therefore, OXT may be referred to as a
novel myokine.
Very few data about OXT effect in regulating gene expression in cell culture are available
in literature. In the present work, considered that our preliminary in vitro results shown
an overexpression of Oxtr mRNA after E2 treatment, we performed combined chronic
treatments of E2 and OXT, the natural ligand of OXTR, to investigate OXT effects in cell
culture. Moreover, chronic treatments with E2 and-or OXT may roughly simulate the
in vivo condition in which animals treated with E2 shown a strong increase of plasmatic
OXT (Divari et al., 2013). The use of OXT in the chronic treatment, despite OXT can
be regulated by E2, was considered necessary for several reasons: (a) the OXT secretion
induced by E2 is very small and a hypothetical effect on muscle cells would have been very
hard to identify, (b) the use of a certain OXT concentration for treatment would allow
authors to clearly establish a causal relationship between treatment and effect. To elicit
the time points for chronic treatments we considered that E2 half-life is estimated to be
around 24 h (Strobl & Lippman, 1979) but a daily medium change could have damaged the
cells. Despite OXT short half-life in vivo (1–2 min in blood and 28 min in cerebrospinal
fluid) (Gimpl & Fahrenholz, 2001), other authors (Cassoni et al., 2002) already performed
treatments with OXT and/or E2 for 48 h in cell culture.
Chronic treatments with E2 and/or OXT did not induce significant morphological
modifications of MTs. This result does not confirm literature which provides few
contradictory data. Kiss & Mikkelsen (2005) described in E2-treated C2C12 MTs a decrease
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of the fusion index by approximately 50% versus the control. On the other side, our result
about Myh downregulation is similar to those reported in Ogawa’s work (Ogawa et al.,
2011) where a significant decrease of the levels of the MYH and MYOG proteins was
described in E2-treated murine satellite cells. MYH is the dominant myofibrillar protein
in differentiated muscle and a downregulation would occur during an inhibitory process.
On the contrary, other authors described that E2 promotes differentiation of rat MB cell
line and induces changes of some differentiation markers such as myogenin and creatine
kinase (Galluzzo et al., 2009; Ronda & Boland, 2016). Unfortunately, a large heterogeneity
exists in literature which includes the use of different cell lines and the choice of different
time points for treatment and evaluation, making difficult to take a definitive conclusion
about E2 effect on muscular differentiation.
A further reflection could be carried out on the modulation of lipid metabolism in the
muscle. Reduction of FABP4 levels has been associated with a better response to insulin
and protective effect against obesity (Makowski & Hotamisligil, 2004). In our study, Fabp4
gene was mildly downregulated by the treatment with OXT only, suggesting a positive
effect of OXT on glucose and lipid metabolism in skeletal muscle, as previously reported
(Elabd & Sabry, 2015). On the contrary, a mild overexpression of Fabp4 was described after
the administration of the combination of E2 and OXT and this data might be related to
a negative influence of high E2 doses on glucose incorporation by MTs, as described by
Garrido et al. (2014), but the responsible mechanisms and the meaning are still unclear.
In conclusion, the detection of a mild but significant downregulation ofMyh may lead
to the hypothesis that in vitromuscular atrophy might be associated with estrogen-induced
glucose and lipid dysmetabolism. The concomitant increase in Oxtr gene expression
and the mild secretion of OXT peptide may be considered as an attempt to restrain the
catabolic process and support glucose uptake. Altszuler & Hampshire (1981) and Lee et al.
(2008) described that OXT is able to induce glucose uptake and increases the plasma insulin
levels. Moreover, Elabd et al. (2014) demonstrated that OXT regulates muscle maintenance
and repair in mice. For these reasons, it is likely that the OXT/OXTR system is involved
in skeletal muscle metabolism and development, but further investigation are needed in
order to better understand the multiple metabolic activities of OXT in skeletal muscle.
CONCLUSIONS
The study demonstrates that the expression of OXT and OXTR increases with the
differentiation process in C2C12 cell line. E2 upregulates OXT and OXTR in C2C12
MTs, similar to the in vivo experiments performed on cattle treated with hormones. This
cell line model could be used for subsequent studies to understand the role of the OXT
peptide on skeletal muscle development and metabolism in relation to E2 administration.
In particular, the non-genomic and genomic mechanisms by which E2 regulates OXT
synthesis/release are of great interest as well as the effects of these two hormones on glucose
and lipid homeostasis.
Since skeletal muscle has been recognized as a secretory organ, OXT could work via
autocrine or paracrine mechanisms to regulate skeletal muscle metabolism. Further studies
Berio et al. (2017), PeerJ, DOI 10.7717/peerj.3124 12/17
are needed to increase our knowledge about estrogen influence onmuscle and its interaction
with OXT.
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